Elixxer Ltd. V.QBA

interesting article ...Freia i am sure will become Big

[massimiliano]

Supplementation with alpha-linolenic acid and inflammation: a feasibility trial


Consumption of omega-3 fatty acids, including the precursor α-linolenic acid (ALA) is often sub-optimal and not in line with international guidelines. Supplementation is debatable, but some individuals, e.g., pre-diabetic, low-grade inflammation, cardiometabolic yet otherwise healthy subjects, might benefit from supra-physiological omega-3 intake, particularly to lessen inflammation. We explored the feasibility of a large clinical trial by performing a pilot study to evaluate adherence, palatability, and self-reported side effects of ALA administration in a group of volunteers. We enrolled 12 individuals with borderline dyslipidemia or overweight, treated with dietary advice according to international guidelines and who had insufficient intakes of essential fatty acids. Subjects were followed for nutritional counselling and were matched with appropriate controls. Patients were administered 6 g/day of ALA, for two months. We report the absence of side effects. such as fishy aftertaste and gastrointestinal distress, in addition to a slight decrease of C-reactive protein concentrations (Identifier: ISRCTN13118704).

Keywords: α-Linolenic acid, diet, inflammation, c-reactive protein, trial, cardiometabolism, adherence

 

Additional information

Acknowledgments

This trial received no external funding. We thank Drs. Alessandro Cavalieri and Michela Dimilta from FREIA Farmaceutici (Milan, Italy) for providing Alfalife™ free of charge.

Disclosure statement

AVG, MB, and FV are members of the scientific board of FREIA Farmaceutici. MC and MTS report no conflict of interest.

https://www.tandfonline.com/doi/abs/10.1080/09637486.2020.1802581?journalCode=iijf20